Radioembolization clinical trials

Explore recruiting radioembolization clinical trials.

Recruiting radioembolization studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Radioembolization trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Radioembolization with Intra-arterial Angiotensin II to improve Tumor-absorbed dose: The RADIANT study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (PM-CARE). Single arm, multicenter phase II study investigating the efficacy and safety of a novel therapeutic scheme in patients with unresectable CholAngiocarcinoma; RadioEmbolization in combination with CisGem and Durvalumab (MEDI4736)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab, versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE).

Belgium, Spain, Italy, France, Germany, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy evaluation of 188Re-SSS lipiodol Selective Internal Radiation Therapy of non operable hepatocellular carcinoma patients, a phase II study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Radioembolization trials by city

Radioembolization in Toronto Radioembolization in Vancouver Radioembolization in Montreal Radioembolization in Calgary Radioembolization in Edmonton Radioembolization in Ottawa Radioembolization in Winnipeg Radioembolization in Quebec City Radioembolization in Hamilton Radioembolization in Kitchener Radioembolization in London Radioembolization in Halifax Radioembolization in New York Radioembolization in Los Angeles Radioembolization in Chicago Radioembolization in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease